Phase 2 Liver Cancer Trial, Recruiting NCT04339036 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT04339036
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of slow-growing tumour called a neuroendocrine tumour (grade 2 or 3) that has spread to the liver and cannot be removed by surgery
  • You have at least one tumour in the liver that is larger than 1 cm in size
  • Most of your tumour burden (50% or more) is located in the liver
  • The tumours take up less than half of your total liver volume
  • The main blood vessel supplying your liver (portal vein) is open and unblocked
  • It has been at least 4 weeks since your last chemotherapy or radiation treatment
  • You are over 18 years old
  • You are expected to live longer than 6 months
  • You are well enough to carry out daily activities (confirm with trial site regarding specific fitness level required)
  • Your liver, kidneys, and blood are functioning well enough to meet specific test thresholds (confirm exact values with trial site)
  • You are willing and able to sign a consent form agreeing to take part
  • If you could become pregnant or father a child, you are willing to use effective contraception, and women of childbearing age must have a negative pregnancy test

Who may not be able to join:

  • You have a medical reason that prevents you from taking the chemotherapy drugs capecitabine or temozolomide
  • You are unable to have both contrast-enhanced MRI and CT scans
  • You have previously been treated with a liver-directed procedure called transarterial embolization (with or without chemotherapy) or Y-90 radioembolization
  • Your blood flow pattern between the liver and lungs makes this type of treatment too risky (confirm with trial site)
  • The treatment cannot be delivered safely without affecting areas outside the liver
  • You do not pass the pre-treatment planning procedure (a special scan called a simulation angiography)
  • You are currently taking part in another clinical trial involving an experimental treatment
  • You have a strong allergy to the dye used in certain scans (iodinated contrast) that cannot be managed with pre-medication
  • You have had certain surgical changes to your bile ducts or the valve between your bile duct and small intestine
  • You have an uncontrolled serious illness, active infection, heart problems, or a mental health or social situation that would make it difficult to follow the study requirements
  • You are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Soulen, University of Pennsylvania

Phone: 855-216-0098

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
7 October 2021
Est. completion
1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Intra-hepatic progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov